Comparative Analysis of Pharmaceutical Industry of Russia and China. Prospects for Cooperation

Author:

Vorontsova Nina1

Affiliation:

1. Baikal State University

Abstract

The purpose of the study is to determine the prospects for cooperation between Russia and China in the development of the pharmaceutical industry based on a comparative analysis of pharmaceutical markets, healthcare systems, regulations, as well as the specifics of the production of pharmaceuticals. Russia and China have similar pharmaceutical markets characterized by the dominance of local companies, low pricing, and high state intervention. However, China's pharmaceutical market is more developed, larger, and more diversified than Russia's. China has a better-funded healthcare system, more favorable regulations, and higher intellectual property protection. China's research and development capabilities are also more advanced, with a higher number of clinical trials, patents, and scientific publications. Russia and China have similar pharmaceutical markets characterized by dominance by local companies, low prices and high levels of government intervention. The Chinese market is much larger, more developed and diversified than the Russian one. And while it continues to face uncertainty amid drug pricing issues and low levels of intellectual property protection, China continues to be one of the most attractive investment destinations in the Asia-Pacific region. However, Russia has a more stable political environment, a well-developed scientific base and highly qualified personnel. The Russian Federation also has a favorable geographical position for logistics and exports. In recent years, the pharmaceutical industry in Russia and China has undergone significant changes, which has led to an increase in global competitiveness. The article analyzes the current state of the pharmaceutical industry of the two countries, highlights the key trends and prospects for cooperation in the future. While both countries have growth potential, there are notable differences in their strengths and weaknesses that may influence future market strategies. In general, the potential for cooperation between Russia and China is great, especially given the current opportunities for expanding international trade and investment.

Publisher

Baikal State University

Reference17 articles.

1. Atkinson R.D. The Impact of China’s Policies on Global Biopharmaceutical Industry Innovation / R.D. Atkinson, Information Technology and Innovation Foundation. 2020. Available at: https://itif.org/publications/2020/09/08/impact-chinas-policies-global-biopharmaceutical-industry-innovation/.

2. Kexin W. Research on the Development Status of China's Pharmaceutical Industry. Rossiya i Aziya = Russia and Asia, 2021, no. 4, pp. 25–34.

3. Li H. One Year Market Exclusivity for Generic Drugs under China’s Patent Linkage Plan, BioCentury, 2021, July 9.

4. Honcharenko D. Pharmaceutical Industry Development: Key Policy Instruments in China. Eureka: Social and Humanities, 2020, no. 4, pp. 3–9. DOI: 10.21303/2504-5571.2020.001369.

5. Shinkevich A.I., Mukhamatgaleeva L.R. Specifics of Pharmaceutical Production Management in the Chinese Industry. Sovremennye naukoemkie tekhnologii= Modern high technologies, 2021, no. 11-2, pp. 307–312. (In Russian). EDN: RWGKGF. DOI: 10.17513/snt.38929.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3